To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN
β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and …

As no specific pharmacological treatment has been validated for use in coronavirus disease
2019 (COVID-19), we aimed to assess the effectiveness of azithromycin (AZM) in these …

Background Tuberculosis has been one of the common diseases of human communities.
Besides of disease-related complications, there are serious adverse reactions due to Anti-…

Objectives To the best of our knowledge, there is no published study regarding use of IFN β-1a
in the treatment of severe COVID-19. In this randomized clinical trial efficacy and safety of …

Background Since the COVID-19 outbreak, pulmonary involvement was one of the most
significant concerns in assessing patients. In the current study, we evaluated patient’s signs, …

Toxoplasma gondii has arisen as an important opportunistic agent especially in the central
nervous system and in advanced HIV disease can cause significant morbidity and mortality. …

Background: COVID-19 has spread globally with remarkable speed, and currently, there is
limited data available exploring any aspect of the intersection between HIV and SARSCoV- 2 …

Tuberculosis is the prototype of infections that require a cellular immune response for their
control. It has been shown that CD4+ T-lymphocytes are most important in the protective …

Background: Diabetes mellitus (along with its complications) has become a global problem.
Diabetic foot infection, among the most common complications, is responsible for 40 to 50% …

Background: Surveillance of health care-associated infections (HCAIs) is an integral part of
infection control programmes, especially in intensive care units (ICUs). Device-associated …